Pazdur’s new FDA role, SITC & China RNAi — a BioCentury podcast

Plus: the plausible mechanism pathway, a gentler MFN and new funds from Medicxi and Sofinnova Partners

Richard Pazdur took the top job at FDA’s Center for Drug Evaluation and Researchafter receiving vows that he would be leading CDER free from political interference. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin and his fellow BioCentury analysts discuss the issues that could prove to be flashpoints between Pazdur and the heads of FDA and HHS, including personnel, RSV mAbs, puberty blockers and SSRIs.

Analysts Lauren Martz and Selina Koch then discuss bispecific innovation at the annual meeting of the Society for Immunotherapy of Cancer (SITC) and the growing field of companies pursuing RNAi, many of which have multiple unpartnered assets. 

BioCentury’s analysts also discuss new funds from European VCs Medicxi and Sofinnova Partners, FDA’s new plausible mechanism pathway and the Trump administration’s “most favored nation” drug-pricing plan, which is turning out to be much more less onerous to drug companies than its original description suggested